Evaluation of the l-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia

Bibliography

• BODEY GP, FREIREICH EJ, MONTO RW, HEWLETT JS: Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults. Cancer Chemother. Rep. (1969) 53:59-66.
   Google Scholar
• MOORE LE, BOUDINOT FD, CHU CK: Preclinical pharmacokinetics of β-dioxolane-cytidine, a novel anticancer agent, in rats. Cancer Chemother. Pharmacol. (1997) 39:532-536.
   PubMed Web of Science ®Google Scholar
• KIM HO, AHN SK, ALVES AJ et al.: Asymmetric synthesis of 1,2-dioxolane-pyrimidine nucleosides and their anti-HIV activity. J. Med. Chem. (1992) 35(11):1987-1995.
   PubMed Web of Science ®Google Scholar
• MANSOUR TS, JIN H, WANG W et al.: Structure–activity relationship among a new class of antiviral and heterosubstituted 2′, 3′-dideoxynucleoside analogues. Nucleosides Nucleotides (1995) 14:627-635.
   Google Scholar
• GROVE KL, GUO X, LIU SH, GAO Z, CHUCK, CHENG YC: Anticancer activity of β-l-dioxolane-cytidine, a novel nucleoside analogue with the unnatural l configuration. Cancer Res. (1995) 55:3008-3011.
   PubMed Web of Science ®Google Scholar
• GOURDEAU H, CLARKE ML, OUELLET F et al.: Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res. (2001) 61:7217-7224.
   PubMed Web of Science ®Google Scholar
• OWENS JK, SHEWACH DS, ULLMAN B et al.: Resistance to 1-β- d-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res. (1992) 52:2389-2393.
   PubMed Web of Science ®Google Scholar
• GATI WP, PATERSON AR, BELCH AR et al.: Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). Leuk. Lymphoma (1998) 32:45-54.
   Web of Science ®Google Scholar
• DE BJS, STEPHENSON JJR, BAKER SD et al.: Troxacitabine, an l-stereoisomeric nucleoside analogue, on a five-times-daily schedule: a Phase I and pharmacokinetic study in patients with advanced solid malignancies. J. Clin. Oncol. (2002) 20(1):96-109.
   Google Scholar
• GOURDEAU H, BIBEAU L, OUELLET F, CUSTEAU D, BERNIER L, BOWLIN T: Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and araC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemother. Pharmacol. (2001) 47:236-240.
   PubMed Web of Science ®Google Scholar
• BOIVIN AJ, GOURDEAU H, MOMPARLER RL: Action of troxacitabine on cells transduced with human cytidine deaminase cDNA. Cancer Invest. (2004) 22(1):25-29.
   PubMed Web of Science ®Google Scholar
• KRISHNAN P, LIOU JY, CHENG Y: Phosphorylation of pyrimidine l-deoxynucleoside analog diphosphates. Kinetics of phosphorylation and dephosphorylation of nucleoside analog diphosphates and triphosphates by 3-phosphoglycerate kinase. J. Biol. Chem. (2002) 277:31593-31600.
   PubMed Web of Science ®Google Scholar
• KRISHNAN P, FU Q, LAM W, LIOU JY, DUTSHMAN G, CHENG YC: Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of l-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J. Biol. Chem. (2002) 277:5453-5459.
   PubMed Web of Science ®Google Scholar
• KRISHNAN P, GULLEN EA, LAM W, DUTSCHMAN GE, GRILL SP, CHENG YC: Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of l-nucleoside analogs, a new class of anticancer and antiviral agents. J. Biol. Chem. (2003) 278:36726-36732.
   PubMed Web of Science ®Google Scholar
• GRANT S: Ara-C: cellular and molecular pharmacology. Adv. Cancer Res. (1998) 72:197-233.
   PubMed Web of Science ®Google Scholar
• CHOU KM, KUKHANOVA M, CHENG YC: A novel action of human apurinic/apyrimidinic endonuclease: excision of l-configuration deoxyribonucleoside analogs from the 3′ termini of DNA. J. Biol. Chem. (2000) 275:31009-31015.
   PubMed Web of Science ®Google Scholar
• GROVE KL, CHENG YC: Uptake and metabolism of the new anticancer compound β-l-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res. (1996) 56(18):4187-4191.
   PubMed Web of Science ®Google Scholar
• LAM W, PARK SY, LEUNG CH, CHENG YC: Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of l-configuration deoxycytidine analogs (troxacitabine and β-l-2′,3′-dideoxy-2′,3′-didehydro-5- fluorocytidine) but not d-configuration deoxycytidine analogs (gemcitabine and β-d-arabinofuranosylcytosine). Mol. Pharmacol. (2006) 69(5):1607-1614.
   PubMed Web of Science ®Google Scholar
• KUKHANOVA M, LIU SH, MOZZHERIN D, LIN TS, CHU CK, CHENG YC: l- and d-enantiomers of 2′,3′-dodepxucutodome 5′-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J. Biol. Chem. (1995) 270:23055-23059.
   PubMed Web of Science ®Google Scholar
• GRIEB P, KORONKIEWICZ M, SKIERSKI JS: Cytostatic and cytotoxic effects of (E)-2′-deoxy-2′- (fluoromethylene)-cytidine on a solid tumor and a leukemia cell line. Acta Biochim. Pol. (2000) 47:165-171.
   PubMed Web of Science ®Google Scholar
• SELEY KL: Tezacitabine Hoechst Marion Roussel. Curr. Opin. Investig. Drugs (2000) 1:135-140.
   Google Scholar
• FINCH RA, LIU M, GRILL SP et al.: Triapine (3-aminopyridine- 2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. (2000) 59:983-991.
   Google Scholar
• GOURDEAU H, GENNE P, KADHIM S et al.: Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts. Cancer Chemother. Pharmacol. (2002) 50:490-496.
   PubMed Web of Science ®Google Scholar
• KIM TE, PARK SY, HSU CH, DUTSCHMAN GE, CHENG YC: Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines. Mol. Pharmacol. (2004) 66(2):285-292.
   PubMed Web of Science ®Google Scholar
• SIU L, ATTARDO G, IZBICKA E et al.: Activity of (-)-2′deoxy-3′-oxacytidine (BCH-4556) against human tumor colony-forming units. Ann. Oncol. (1998) 9:885-891.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ PM, HAGGERTY JG, CHENG YC: β-l-1,3-dioxolane-cytidine: a novel nucleoside that inhibits proliferation and induces differentiation of keratinocytes in vitro. Skin Pharmacol. Appl. Skin Physiol. (1998) 11(4-5):207-213.
   Google Scholar
• KHADIM S, BOWLIN TL, WAUD WR et al.: Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (β-l-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res. (1997) 57(21):4803-4810.
   PubMed Web of Science ®Google Scholar
• ATTARDO G, KADHIM S, ANGERS E, BIBEAU L, BOWLIN L: Dose scheduling effects on the antitumor activity of BCH-4556 against human tumor xenografts in nude mice. Proc. Am. Assoc. Cancer Res. (1997) 38:100.
   Google Scholar
• RABBANI SA, HARAKIDAS P, BOWLIN T, ATTARDO G: Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Res. (1998) 58(15):3461-3465.
   PubMed Web of Science ®Google Scholar
• WEITMAN S, MARTY J, JOLIVET J, LOCAS C, VON HOFF DD: The new dioxolane, (-)-2′-deoxy-3′-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin. Cancer Res. (2000) 6:1574-1578.
   Google Scholar
• ORSOLIC N, GILES FJ, GOURDEAU H et al.: Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. Br. J. Haematol. (2004) 124(6):727-738.
   PubMed Web of Science ®Google Scholar
• GOURDEAU H, LEBLOND L, HAMELIN B et al.: Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development. Clin. Cancer Res. (2004) 10:7692-7702.
   Google Scholar
• BELANGER K, MOORE M, BAKER SD et al.: Phase I and pharmacokinetic study of novel l-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. J. Clin. Oncol. (2002) 20:2567-2574.
   Google Scholar
• CANOVA A, YEE L, BAKER S: A Phase I and pharmacokinetic study of β-l-dioxalo-cytidine (BCH-4556) administered weekly for three weeks every 28 days. Proc. Am. Soc. Clin. Oncol. (1999) 18:197.
   Google Scholar
• STEPHENSON JRJ, BAKER SD, AYLESWORTH C: A Phase I safety and pharmacokinetic study of BCH-4556, a novel l-nucleoside antimetabolite, on a daily x 5 day every 21-day schedule in patients with solid neoplasms. Ann. Oncol. (1998) 9(Suppl. 2):156
   Web of Science ®Google Scholar
• BAKER SD, STEPHENSON J, GOETZ A: Determinants affecting β-l-dioxolane-cytidine (BCH-4556) exposure and relationship with toxicity in Phase I trials. Proc. Am. Soc. Clin. Oncol. (1999) 18:197.
   Google Scholar
• DE BONO JS, STEPHENSON JJ, BAKER SD et al.: Troxacitabine, and l-stereoisomeric nucleoside analog, on a five-times-daily schedule: a Phase I and pharmacokinetic study in patients with advanced solid malignancies. J. Clin. Oncol. (2002) 20(1):96-109.
   Google Scholar
• GILES FJ, CORTES JE, BAKER SD et al.: Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J. Clin. Oncol. (2001) 19(3):762-771.
   Google Scholar
• GILES FJ, GARCIA-MANERO G, CORTES JE et al.: Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J. Clin. Oncol. (2002) 20:656-664.
   Google Scholar
• SACCHI S, KANTARJIAN HM, O’BRIEN S et al.: Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer (1999) 86:2632-2641.
   PubMed Web of Science ®Google Scholar
• GILES FJ, FELDMAN EJ, ROBOZ GJ et al.: Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk. Res. (2003) 23:1091-1096.
   Google Scholar
• GILES FJ, FADERL S, THOMAS DA et al.: Randomized Phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J. Clin. Oncol. (2003) 21:1050-1056.
   Google Scholar
• GILES FJ, KANTARJIAN HM, CORTES JE et al.: Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J. Clin. Oncol. (2003) 21:1722-1727.
   Google Scholar
• ROBOZ G, GILES FJ, RITCHIE EK et al.: Phase I/II study of troxacitabine administered by continuous infusion in patients with refractory acute myeloid leukemia. J. Clin. Oncol. (2006) 25(1):10-15.
   Google Scholar
• LEE CK, ROWINSKY EK, LI J et al.: Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. Clin. Cancer Res. (2006) 12(7):2158-2165.
   Google Scholar